Figure 5. Perhexiline favours NB cell transition to differentiated phenotype in vivo.

Real-time RT-PCR quantification of differentiation marker (NF68) and stemness marker (C-Kit), in the tumour nodules. Protocol a (vehicle, Perhexiline 1 mg/Kg/dose and/or Cisplatin 3 mg/Kg/dose) (a), protocol b (vehicle, Perhexiline 3 mg/Kg/dose and/or Cisplatin 5 mg/Kg/dose) (b). One star (*) indicates p < 0.05, while two stars (**) indicate p < 0.001, two-tailed Student’s test.